Therapeutic effect of boron neutron supplementation therapy with PDL1 antibody for advanced bladder cancer (including metastasis)

• Project/Area Number: 21K09386
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Osaka Medical and Pharmaceutical University
• Principal Investigator: 東 治人 大阪医科薬科大学, 医学部, 教授 (40231914)
• Co-Investigator(Kenkyū-buntansha): 鈴木 実 京都大学, 複合原子力科学研究所, 教授 (00319724) ; 小野 公二 大阪医科薬科大学, BNCT共同臨床研究所, 所長 (90122407) ; 稲元 輝生 大阪医科薬科大学, 医学部, 准教授 (20330087) ; 小村 和正 大阪医科薬科大学, 医学部, 講師 (10789853) ; 上原 博史 大阪医科薬科大学, 医学部, 准教授 (20822555)
• Project Period (FY): 2021-04-01 – 2026-03-31
• Project Status: Granted (Fiscal Year 2023)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2025: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2024: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2023: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2022: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000); Fiscal Year 2021: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
• Keywords: 膀胱温存 / 浸潤癌 / BOAI / BNCT

Outline of Research at the Start

①膀胱、および、骨盤内リンパ組織に極めて高濃度の硼素化合物を投与可能とする“BOAI法”を用いて、膀胱癌細胞、特に核内に選択的に集積、移行するべく特殊加工した“膀胱癌細胞親和性硼素化合物（現在作成中）”を投与することによって、膀胱癌細胞により選択的に高濃度の硼素化合物を取り込ませ、癌細胞を選択的に破壊するBOAI-BNCT法の開発、および、②　ICI併用による転移抑制効果（アブスコパル効果）の検討

Outline of Annual Research Achievements

本研究は、血流塞栓膀胱動脈選択的動脈内投与法（baloon occluded arterial infusion: BOAI法）と癌選択的な標的粒子線治療“硼素中性子捕捉療法(BNCT)”を併用すること（BOAI-BNCT療法）によって、副作用が極めて少ない新規膀胱温存治療を開発・臨床応用すること、および、免疫チェックポイント阻害薬併用によるアブスコパル効果の増強を期待した転移抑制を目的としている。BOAI-BNCT療法とは“癌選択的な標的粒子線治療” 硼素中性子捕捉療法（BNCT）は、癌細胞選択的に取り込まれる硼素（10B）化合物を予め投与しておき、熱中性子線を照射することにより、10Bを殆ど取り込まない正常細胞は障害されないが、10Bを多く取り込んだ癌細胞では細胞内部で硼素と熱中性子の核反応が生じ、核反応により発生した高エネルギーのα線と7Li粒子が癌細胞を選択的に破壊する、「正常組織温存＋癌細胞選択的破壊治療」である。本治療法の大きな利点は、核反応により発生するα線も7Li粒子も飛距離１０ミクロン以下のため、周囲細胞に影響を及ぼさず、硼素を取り込んだ癌細胞のみを選択的に破壊できることであり、また、本治療の成否は、いかに十分量の硼素化合物を癌細胞に選択的に集積させるかにかかっている。そこで我々は、膀胱、および、骨盤内リンパ組織に極めて高濃度の硼素化合物を投与可能とする“BOAI法”（血流塞栓用バルーン付カテーテルを用いて膀胱動脈選択的に硼素化合物を動脈内投与する）を用いて、膀胱癌細胞、特に核内に選択的に集積、移行するべく特殊加工した“膀胱癌細胞親和性硼素化合物（現在作成中）”を投与することによって、膀胱癌細胞により選択的に高濃度の硼素化合物を取り込ませ、癌細胞を選択的に破壊するBOAI-BNCT法を開発している。

Current Status of Research Progress

2: Research has progressed on the whole more than it was originally planned.

Reason

転移の部位、状態が目で見てわかる“マウスビジュアル膀胱癌転移モデル”を用いたBOAI-BNCT療法の治療効果の確認
１、“マウスビジュアル膀胱癌転移モデル”：臨床的に非常に重要な“転移のメカニズムと治療”について、これまで有用な動物モデルがないため研究が進まなかったが、我々は膀胱癌細胞株T24のゲノム内にLuciferase発現遺伝子を導入したFSR-T24を作成し、これをマウスに移植することによって転移の部位、状態が目で見てわかる、マウスビジュアル膀胱癌転移モデルを確立した (癌細胞が複性した後にも発光することによって、転移巣をビジュアルで確認できる)。
２、作成方法：ヌードマウスの陰茎背静脈からLuciferase発現遺伝子を導入したFSR-T24を107 ずつ静脈内投与する。　腫瘍細胞は約1か月後に肺、肝臓で多発する転移巣を形成し、蛍光発光するため体表からも観察可能である。　N=20
３、硼素化合物の癌細胞選択的移行の確認：マウスビジュアル膀胱癌転移モデルに硼素化合物を静注投与し、各転移巣における硼素化合物の取り込み状況をKUR-BSH定量システムを用いて定量し、また、核内移行を免疫組織染色により確認する。
４、治療効果の確認：硼素化合物投与後、中性子を照射し癌細胞を選択的に破壊する。転移巣の大きさは目で見て測定可能であり、血液データをチェックすることにより、治療効果と副作用を同時に判定しつつ、生存期間の延長も検討でき、実際の臨床に即した極めて有用なモデルである。

Strategy for Future Research Activity

免疫チェックポイント阻害薬（ICI）併用による転移抑制効果の検討:
近年、放射線療法による癌免疫賦活は多く報告されており、当科でも骨転移に放射線照射を施行した際、肺転移が著明に縮小した症例を経験している。そこで、BNCTにICIを併用投与することよる転移抑制効果を検討する。ICIは作用が発現するまである程度時間がかかることが少なくないこと、また、効果の部位は全身に発現することが予想されることから、転移巣の大きさ、血液データを継続的に測定可能である当モデルは極めて有用であると思われる。また、作用機序や、サロゲートマーカーなどを詳細に検討可能であり、同時に、生存期間の延長も検討できることなど、今後の実臨床に貢献する極めて有用な研究課題であると期待している。

Research Products

• [Journal Article] Importance of Management of Lifestyle-Related Diseases After Kidney Donation to Living Donors (2024)
  • Author(s): Hirano H,Fujiwara Y,Okabe T, Nakamori K,Minami K,Uehara H, Nomi H,Komura K,Inamoto T, Azuma H.
  • Journal Title: Transplantation Proceedings Volume: 56 Issue: 3 Pages: 479-81
  • DOI: 10.1016/j.transproceed.2024.01.027
  • Peer Reviewed / Open Access
• [Journal Article] Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma (2023)
  • Author(s): Inamoto T,Sato R,Matsushita Y,Uchimoto T,Nakamuran K.O, Komura K , Nishimura N,Yano Y, Nishio K,Kinoshita S,Fukushima T,Matsunaga T, Nakamori K,Tsutsumi T,Tsujino T,Uehara H,Takahara K, Miyake H,Azuma H.
  • Journal Title: Cancer Diagnosis & Prognosis Volume: 3 Issue: 3 Pages: 370-6
  • DOI: 10.21873/cdp.10226
  • Peer Reviewed / Open Access
• [Journal Article] Usefulness of Dietary Salt Restriction in Kidney Transplant Recipients: Analysis of Blood Pressure Levels Depending on the Differences in the Levels of Salt Intake (2023)
  • Author(s): Hirano H,Fujiwara Y, Maenosono R,Minami K,Uehara H,Okabe T, Nakamori K,Nomi H,Komura K, Inamoto T,Azuma H.
  • Journal Title: Transplantation Proceedings Volume: 55 Issue: 4 Pages: 841-4
  • DOI: 10.1016/j.transproceed.2023.03.054
  • Peer Reviewed / Open Access
• [Journal Article] Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial (2023)
  • Author(s): Kimura T,Ishikawa H,Nagumo Y,Sekino Y,Kageyama Y,Ushijima H,Kawai T,Yamashita H, Azuma H, Nihei K, Takemura M, Hashimoto K,Maruo K,Tsuzuki T, Nishiyama H.
  • Journal Title: International Journal of Radiation Oncology*Biology*Physics Volume: 117 Issue: 3 Pages: 644-51
  • DOI: 10.1016/j.ijrobp.2023.05.013
  • Peer Reviewed / Open Access
• [Journal Article] Platelet count and dose, but not comorbidities, predict severe neutropenia in cabazitaxel-treated prostate cancer patients: A?retrospective observational study (2023)
  • Author(s): Kataoka N,Hata T, Hosomi K, Hirata A, Goto E, Nishihara M, Inamoto T,Azuma H, Neo M.
  • Journal Title: Int. Journal of Clinical Pharmacology and Therapeutics Volume: 61 Issue: 09 Pages: 386-93
  • DOI: 10.5414/cp204393
  • Peer Reviewed / Open Access
• [Journal Article] Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer (2023)
  • Author(s): Tsujino Takuya, Tokushige Satoshi, Komura Kazumasa, et al
  • Journal Title: Cancer Medicine Volume: 12 Issue: 19 Pages: 19414-19422
  • DOI: 10.1002/cam4.6536
  • Peer Reviewed / Open Access
• [Journal Article] Tertiary lymphoid structure and neutrophil?lymphocyte ratio coordinately predict outcome of pembrolizumab (2023)
  • Author(s): Komura K,Tokushige S, Ishida M, Hirosuna K,Yamazaki S,Nishimura K,Ajiro M,Ohno T,Nakamori K,Kinoshita S,Tsujino T, Maenosono R,Yoshikawa Y, Takai T, Tsutsumi T,Taniguchi K,Tanaka T,Takahara K, Inamoto T,Hirose Y, Ono F,Shiraishi Y,Yoshimi A,Azuma H.
  • Journal Title: Cancer Science Volume: 114 Issue: 12 Pages: 4622-31
  • DOI: 10.1111/cas.15976
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma (2023)
  • Author(s): Tsujino T,Komura K,Inamoto T,Maenosono R,Hashimoto T, Adachi T, Hirasawa Y,Tokushige S,Ohno T,Yamazaki S,Fukushima T,Nakamura K,Yano Y,Nishimura K,Kinoshita S,Nakamori K,Tsutsumi T,Matsunaga T,Yoshikawa Y,Uchimoto T,Takai T,Minami K,Uehara H,Hirano H,Nomi H,Takaraha K,Ohno Y,Azuma H.
  • Journal Title: World Journal of Urology Volume: 41 Issue: 12 Pages: 3585-91
  • DOI: 10.1007/s00345-023-04687-3
  • Peer Reviewed / Open Access
• [Journal Article] The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer (2023)
  • Author(s): Komura K, Hirosuna K, Tokushige S, Nishimura K, Ishida M, Hayashi T, Ura A, Ohno T, Yamazaki S, Nakamori K, Kinoshita S, Tsujino T, Maenosono R, Ajiro M, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Konuma T, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A#, Azuma H.
  • Journal Title: Molecular Cancer Volume: 22 Issue: 1 Pages: 185-185
  • DOI: 10.1186/s12943-023-01897-6
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Bronchogenic cysts in rare sites (retroperitoneum, skin, spinal cord and pericardial cavity): A case series and characterization of epithelial phenotypes (2023)
  • Author(s): Onish Y,Kawabata S,Yasuda E, Ibuki N, Azuma H, Hirota Y, Ueda K, Neo M, Daimon M, Kurisu Y, Hirose Y.
  • Journal Title: Biomedical Reports Volume: 20 Issue: 2 Pages: 1-8
  • DOI: 10.3892/br.2023.1709
  • Peer Reviewed / Open Access
• [Journal Article] Real‐world outcomes of avelumab plus axitinib as first‐line therapy in patients with advanced renal cell carcinoma in Japan: A?multicenter, retrospective, observational study (J‐DART) (2023)
  • Author(s): Kato T,Nakano Y, Hongo F, Katano H, Miyagawa T,Ueda K, Azuma H,Nozawa M, Hinata N, Hori J,Otoshi T,Shimizu N,Aizawa M,Osada S,Matsui A, Oya M, Eto M, Tomita Y,Shinohara N, Uemura H.
  • Journal Title: International Journal of Urology Volume: 31 Issue: 3 Pages: 265-72
  • DOI: 10.1111/iju.15345
  • Peer Reviewed / Open Access
• [Journal Article] Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer (2023)
  • Author(s): ICHIHASI A、INAMOTO T、UCHIMOTO T、NAKAMURA K、KOMURA K、YANO Y、NISHIMURA K、KINOSHITA S、NISHIO K、FUKUSHIMA T、NAKAMORI K、MATSUNAGA T、TSUTSUMI T、TSUJINO T、UEHARA H、TAKAHARA K、YAMAMOTO K、KATO R、IJIRI Y、HAYASHI T、AZUMA H.
  • Journal Title: In Vivo Volume: 37 Issue: 1 Pages: 143-148
  • DOI: 10.21873/invivo.13063
  • Peer Reviewed / Open Access
• [Journal Article] CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. (2023)
  • Author(s): Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Kent W. Mouw, Szallasi Z, Zou L,Kibel1 AS, Jia L.
  • Journal Title: Nature Communications Volume: 14 Issue: 1 Pages: 1-19
  • DOI: 10.1038/s41467-023-35880-y
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival (2022)
  • Author(s): Nakamori K, Yamazaki S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Ohno T, Yano Y, Nishimura K, Tokushige S, Uchimoto T, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H.
  • Journal Title: Clin Transl Radiat Oncol. Volume: 39 Pages: 5659-5659
  • DOI: 10.1016/j.ctro.2022.12.001
  • Peer Reviewed / Open Access
• [Journal Article] Prognostic value of the fluctuation in the neutrophil lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma. (2022)
  • Author(s): Uchimoto T,Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Kimura T, Egawa S, Azuma H.
  • Journal Title: Urologic oncology Volume: 40 Issue: 7 Pages: 11-17
  • DOI: 10.1016/j.urolonc.2022.02.012
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Unplanned hemodialysis initiation and low geriatric nutritional risk index scores are associated with end-stage renal disease outcomes. (2022)
  • Author(s): Maenosono R,Fukushima T, Kobayashi D, Matsunaga T, Yano Y, Taniguchi S, Fujiwara Y, Komura K, Uehara H, Kagitani M, Hirano H, Inamoto T, Nomi H, Azuma H.
  • Journal Title: Scientific Reports Volume: 12 Issue: 1 Pages: 11101-11101
  • DOI: 10.1038/s41598-022-14123-y
  • Peer Reviewed / Open Access
• [Journal Article] Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. (2022)
  • Author(s): Yoshikawa Y, Stopsack KH, Wang V, Chen YH, Mazzu YZ, Burton F, Chakraborty G, Rajanala SH, Hirani R, Nandakumar S,Lee GM, Flank D, Davicioni E, Liu G, Carducci MA, Azuma H, Kantoff PW, Sweeney CJ.
  • Journal Title: Mol. Oncol Volume: 16 Issue: 22 Pages: 3994-4010
  • DOI: 10.1002/1878-0261.13314
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab. (2022)
  • Author(s): Yano Y, Ohno T, Komura K, Fukuokaya W, Uchimoto T, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Yamazaki S, Tokushige S, Nishimura K, Tsujino T, Nakamori K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H.
  • Journal Title: Cancers Volume: 14 Issue: 22 Pages: 5659-69
  • DOI: 10.3390/cancers14225659
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer (2022)
  • Author(s): Nishimura ｋ, Nishio K, Hirosuna K,Komura K, Hayashi T,Fukuokaya W, Ura A,Uchimoto T, Nakamura K, Fukushima T,Yano Y,Takahashi N, Nakamori K, Kinoshita S,Matsunaga T, Tsutsumi T,Tsujino T,Taniguchi K,Tanaka T,Uehara H, Takahara K,Inamoto T,Hirose Y,Kimura T,Egawa S,Azuma H.
  • Journal Title: Journal for ImmunoTherapy of Cancer Volume: 10 Issue: 1 Pages: e003868-e003868
  • DOI: 10.1136/jitc-2021-003868
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Outcomes of sorafenib treatment of advanced renal cell carcinoma according to International Metastatic Renal Cell Carcinoma Data Consortium risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib. (2022)
  • Author(s): Inamoto T, Azuma H, Adachi M, Okayama Y, Sunaya T,Oya M.
  • Journal Title: Future Oncol . Volume: 18(11) Issue: 11 Pages: 1371-1380
  • DOI: 10.2217/fon-2021-1001
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. (2022)
  • Author(s): Tsujino T,Miao C, Takai T,Gui F, Tsutsumi T,Sztupinszki Z, Wang Z, Azuma H,Szallasi Z,Mouw K.W,Zou L,Kibel A.S,Jia L.
  • Journal Title: Scinece Advances Volume: 8(7) Issue: 7
  • DOI: 10.1126/sciadv.abl9794
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study). (2021)
  • Author(s): Kobayashi K,Matsuyama H,Kawai T, Ikeda A,Miyake M,Nishimoto K, Matsushita Y, Komura K,Abe T, Kume H, Nishiyama H, Fujimoto K,Oyama M, Miyake H, Inoue K,Mitsui T,Kawakita M,Ohyama C, Mizokami A,Kuroiwa H.
  • Journal Title: International Journal of Urology Volume: online Issue: 7 Pages: 1-7
  • DOI: 10.1111/iju.14854
  • Peer Reviewed / Open Access
• [Journal Article] Recipient sex and estradiol levels affect transplant outcomes in an age-specific fashion. (2021)
  • Author(s): Maenosono R, Nian Y, Iske J,Minami K, Rommel T, Martin F, Abdi R,Azuma H, Rosner BA, Zhou H, Milford E, Elkhal A, Tullius SG.
  • Journal Title: American Journal of Transplantation Volume: 21(10) Issue: 10 Pages: 3239-55
  • DOI: 10.1111/ajt.16611
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan. (2021)
  • Author(s): Uchimoto T,Komura K,Fukuokaya W, Kimura T,Takahashi K, Yano Y, Nishimura K Nakamori K,Fujiwara Y,Matsunaga T,Tsutsumi T,Tsujino T, Maenosono R,Yoshikawa Y,Taniguchi K,Tanaka T,Uehara H, Hirano H,Nomi H,Takahara K,Inamoto T,Egawa S, Azuma H.
  • Journal Title: Cancers Volume: 13(14)3554 Issue: 14 Pages: 1-10
  • DOI: 10.3390/cancers13143554
  • Peer Reviewed / Open Access
• [Journal Article] Hemodialysis Initiation in Oldest-Old Patients: A Case Series. (2021)
  • Author(s): Maenosono R,Matsunaga T,Yoshikawa Y,Nishimura K,Onaka H, Komura K, Uehara H,Azuma H.
  • Journal Title: Case Rep Nephrol Dial Volume: 11 Issue: 3 Pages: 286-91
  • DOI: 10.1159/000518706
  • Peer Reviewed / Open Access
• [Journal Article] Taurodeoxycholic acid and valine reverse obesity-associated augmented alloimmune responses and prolong allograft survival. (2021)
  • Author(s): Quante M, Iske J, Uehara H, Minami K, Nian Y, Maenosono R, Matsunaga T, Liu Y, Azuma H, Perkins D, Alegre ML, Zhou H, Elkhal A, Tullius SG.
  • Journal Title: American Journal of Transplantation Volume: 22 Issue: 2 Pages: 402-13
  • DOI: 10.1111/ajt.16856
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents (2021)
  • Author(s): Komura Kazumasa、Inamoto Teruo、Tsujino Takuya、Matsui Yusuke et al.
  • Journal Title: Oncogene Volume: 40 Issue: 43 Pages: 6210-6222
  • DOI: 10.1038/s41388-021-02021-y
  • Peer Reviewed / Open Access
• [Journal Article] The potential of Senolytics in transplantation. (2021)
  • Author(s): Matsunaga T,Iske J, Schroeter A,Azuma H,Zhou H,Tullius SG.
  • Journal Title: Mechanisms of Ageing and Development. Volume: 200(2021) Pages: 111582-111582
  • DOI: 10.1016/j.mad.2021.111582
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer (2021)
  • Author(s): Tsujino T,Komura K, Inamoto T, Azuma H.
  • Journal Title: International Journal of Molecular Sciences Volume: 22 Issue: 23 Pages: 12777-12777
  • DOI: 10.3390/ijms222312777
  • Peer Reviewed / Open Access
• [Journal Article] 筋層浸潤性膀胱癌に対する新規治療戦略：膀胱温存療法のさらなる発展に向けて (2021)
  • Author(s): 東 治人,小村和正、上原博史、新保大樹、山本和宏、稲元輝生.
  • Journal Title: 泌尿器外科 Volume: 34（11） Pages: 1245-56
  • Peer Reviewed / Open Access
• [Presentation] Management of alpha-herpesvirus infection following kidney transplantation: Our experience (14 cases) (2023)
  • Author(s): Uehara H,Hirano H, Matsunaga T,Minami K,Komura K,Ibuki N, Inamoto T,Nomi H,Azuma H.
  • Organizer: 第100回日本泌尿器科学会総会
• [Presentation] Re-challenging Chemotherapy after Pembrolizumab in Platinum-Refractory Urothelial Carcinoma. (2023)
  • Author(s): Uchimoto T,Komura K, Fukuokaya W, Adachi T, Yoshizawa A, Hashimoto T, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H.
  • Organizer: 第110回日本泌尿器科学会総会
• [Presentation] Correlation between genetic alterations fibroblast growth factor recepters and immune-microenvironment profiles in bladder cancer. (2023)
  • Author(s): Nishimur K,Komura K,Hirosuna K,Hayashi T,Ura A,Tsujino T,Uchimoto T,Minami K,Uehara H,Inamoto T,Yoshimi A, Azuma H.
  • Organizer: 第110回日本泌尿器科学会総会
• [Presentation] Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab. (2023)
  • Author(s): Yano Y,Ohno T, Komura K,Fukuokaya W,Uchimoto T, Adachi T,Hirasawa Y,Hashimoto T, Yoshizawa A,Yamazaki S,Tokushige S, Nishimura K,Tsujino T,Nakamori K,Yamamoto S,Iwatani K,Urabe F,Mori K,Yanagisawa T,Tsuduki S,Takahara K,Inamoto T,Miki J,Kimura T,Ohno Y,Shiroki R, Azuma H.
  • Organizer: 第110回日本泌尿器科学会総会
• [Presentation] Accelerated Senescence is playing a critical role in chronic allograft dysfunction. (2023)
  • Author(s): Matsunaga T,Nakamori K, Azuma H.
  • Organizer: ATC 2023
  • Int'l Joint Research
• [Presentation] Importance of management of lifestyle-related diseases after kidney donation to living donors. (2023)
  • Author(s): Hirano H,Fujiwara Y, Okabe T,Nakamori K, Maenosono R, Minami K,Uehara H, Nomi H,Komura K,Inamoto, Azuma H.
  • Organizer: CAST2023
  • Int'l Joint Research
• [Presentation] 限局性膀胱癌に対する膀胱温存療法の年齢層別解析. (2023)
  • Author(s): 稲元輝生、辻野拓也、前之園良一、西村一希、中村公、大野貴也、髙井朋聡、小村和正、上原博史、平野一、能見勇人、東治人.
  • Organizer: 第73回日本泌尿器科学会中部総会
• [Presentation] The association between outcome and malnutrition score in hemodialysis associated renal cancer patients. (2023)
  • Author(s): Maenosono R,Okabe T,Shinmyo T, Hanamori T, Goji K,Tsujino T, Uehara H,Komura K,Hirano H, Nomi H,Inamoto T,Azuma H.
  • Organizer: AOS2023
  • Int'l Joint Research
• [Presentation] Elucidating Key Genetic Determinants of PARP Inhibitor Sensitivity in Prostate Cancer through Genome-wide CRISPR-Cas9 Screening. (2023)
  • Author(s): Tsujino T,Takai T , Komura K, Inamoto T, Azuma H.
  • Organizer: AOS 2023
  • Int'l Joint Research
• [Presentation] Re-challenging Chemotherapy after Pembrolizumab in Platinum-Refractory Urothelial Carcinoma. (2023)
  • Author(s): Uchimoto T,Komura K, Fukuokaya W, Adachi T, Yoshizawa A, Hashimoto T, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki Ri, Egawa S, Azuma H.
  • Organizer: The 3rd Interanational Cogress of the Asisan Oncology Society
  • Int'l Joint Research
• [Presentation] A case of donated kidney transplantation for Charcot-Marie-Tooth disease with renal failure. (2023)
  • Author(s): Nakamura K,Hirano H,Fujiwara Y,Okabe T,Minami K,Komura K,Inamoto T,Nomi H,Azuma H.
  • Organizer: THE 18TH CONGRESS OF ASIAN SOCIETY OF TRANSPLANTATION
  • Int'l Joint Research
• [Presentation] 根治的化学放射線療法後の転移性膀胱癌におけるPembrolizumab有効性/包括的PD-L1解析. (2022)
  • Author(s): 西村一希,小村和正,木村高弘,林大久夫,内本泰三,福岡屋航,浦礼子,上原博史,平野 一,稲元輝生,能見勇人,廣瀬善信,穎川晋,東 治人.
  • Organizer: 第60回日本癌治療学会学術集会
• [Presentation] 当院での生体腎移植後患者における、新型コロナウイルスワクチンの有用性 (2022)
  • Author(s): 岡部知太,平野 一, 前之園 良一,中森啓太, 藤原裕也,南 幸一郎, 上原博史, 能見勇人,稲元輝生, 東 治人.
  • Organizer: 第58回日本移植学会総会
• [Presentation] 当院における腎移植後患者における悪性腫瘍発生について (2022)
  • Author(s): 南 幸一郎,岡部知太,前之園 良一,藤原裕也,中森啓太,上原博史,平野 一,能見勇人,東 治人 .
  • Organizer: 第58回日本移植学会総会
• [Presentation] 上部尿路腫瘍に対する臓器温存の経験と生検病理組織の解析 (2022)
  • Author(s): 稲元輝生、中森啓太、徳永雄希、前之園 良一、辻野拓也、南 幸一郎、小村和正、上原博史、能見勇人、東 治人.
  • Organizer: 第43回日本レーザー医学会総会
• [Presentation] HoとNdによるUTUC治療と成績 (2022)
  • Author(s): 稲元輝生、中森啓太、徳永雄希、前之園 良一、辻野拓也、南 幸一郎、小村和正、上原博史、能見勇人、東 治人.
  • Organizer: 第36回日本泌尿器内視鏡・ロボティクス学会総会
• [Presentation] 過活動膀胱と夜間頻尿 (2022)
  • Author(s): 東 治人.
  • Organizer: 第９回 市民公開講座 大阪腎泌尿器疾患研究財団
  • Invited
• [Presentation] 高感作の腎移植候補患者での治療にかかる医療費の検討 (2022)
  • Author(s): 前之園 良一、海上耕平、大木 里花子、藤原裕也、八木澤 隆史、神澤太一、尾本和也、東 治人、石田英樹、高木敏男.
  • Organizer: 第72回日本泌尿器科学会中部総会
• [Presentation] Cost Effectiveness of Kidney Transplantation in High-Immunological Risk Patients in a Japan Cohort (2022)
  • Author(s): Maenosono R,Unagami k, Oki R, Fujiwara Y, Yagisawa T,Kanzawa T,Hirai T,Omoto K,Azuma H,Ishida H, Takagi T.
  • Organizer: Transplantation Science Symposium(TSS) Asian Regional Meeting 2022
  • Int'l Joint Research
• [Presentation] Recipient sex hormone affect transplant outcomes in an age-specific fashion (2022)
  • Author(s): Maenosono R,Nian Y, Iske J,Azuma H,Tullius S.G.
  • Organizer: Transplantation Science Symposium(TSS) Asian Regional Meeting 2022
  • Int'l Joint Research
• [Presentation] Re-challenging Chemotherapy in Patients with Platinum-Refractory Urothelial Carcinoma Previously Treated with Pembrolizumab. (2022)
  • Author(s): Uchimoto T,Komura K, Fukuokaya W, Adachi T, Yoshizawa A, Hashimoto, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H.
  • Organizer: 第60回日本癌治療学会学術集会
• [Presentation] Usefulness Of Dietary Salt Restriction In Kidney Transplant Recipients: Analysis Of Blood Pressure Levels Depending On The Differences In The Levels Of Salt Intake (2022)
  • Author(s): Hirano H,Fujiwara Y, Maenosono R,Minami K,Uehara H,Okabe T,Nakamori K, Nomi H,Komura K,Inamoto T, Azuma H.
  • Organizer: 2022 TSS
  • Int'l Joint Research
• [Presentation] Occurrence of Malignant Tumors in Post-Renal Transplant Patients at Our Hospital (2022)
  • Author(s): Minami K,Hirano H, Uehara H,Komura K, Maenosono R,Fujiwara Y,Okabe T, Nakamori K,Inamoto T,Nomi H, Azuma H.
  • Organizer: 2022 TSS
  • Int'l Joint Research
• [Presentation] 膀胱がんの病態と診断 (2021)
  • Author(s): 東 治人
  • Organizer: 第8回市民公開講座
  • Invited